Wien Center for Alzheimer's Disease
Welcome,         Profile    Billing    Logout  
 6 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Duara, Ranjan
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
LEADS, NCT03507257: Longitudinal Early-onset Alzheimer's Disease Study Protocol

Recruiting
N/A
700
Europe, US, RoW
Flortaucipir, 18F-AV-1451 (also known as [F-18]T807 or LY3191748), Florbetaben, AV-45, Neuraceq, Fluorodeoxyglucose, FDG
Indiana University, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA), Alzheimer's Association
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
05/25
05/25
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Nieves, Anette
NCT05357989: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
10/24
10/24
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
ENVISION, NCT05310071: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen
Alzheimer's Disease
08/24
08/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
320
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Active, not recruiting
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia With Lewy Bodies
11/24
11/24
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
Rodriguez, Rosemarie A
LEADS, NCT03507257: Longitudinal Early-onset Alzheimer's Disease Study Protocol

Recruiting
N/A
700
Europe, US, RoW
Flortaucipir, 18F-AV-1451 (also known as [F-18]T807 or LY3191748), Florbetaben, AV-45, Neuraceq, Fluorodeoxyglucose, FDG
Indiana University, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA), Alzheimer's Association
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
05/25
05/25

Download Options